For the year ending 2025-12-31, ABCL had -$28,366K decrease in cash & cash equivalents over the period. -$174,067K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -146,412 |
| Depreciation of property and equipment | 18,439 |
| Amortization and impairment of intangible assets | 3,732 |
| Amortization of operating lease right-of-use assets | 6,650 |
| Stock-based compensation | 55,792 |
| Fair value (gain) loss on contingent consideration and investments | -4,529 |
| Other | 3,331 |
| Research fees and grants receivable | 55,623 |
| Income taxes (payable) receivable | -29,843 |
| Accounts payable and accrued liabilities | 3,457 |
| Deferred revenue | -2,195 |
| Deferred grant income | 3,638 |
| Other assets | -17,148 |
| Net cash used in operating activities | -131,295 |
| Purchases of property and equipment | 42,772 |
| Purchase of marketable securities | 436,044 |
| Proceeds from marketable securities | 506,072 |
| Receipt of grant funding | 21,343 |
| Distribution from equity accounted investees | 30,113 |
| Investment in and loans to equity accounted investees | 7,137 |
| Proceeds from repayment of loan from joint venture partner | -33,268 |
| Long-term investments and other assets | 17,093 |
| Net cash provided by (used in) investing activities | 87,750 |
| Payment of liability for in-licensing agreement and other | 15,649 |
| Proceeds from long-term liabilities and other | 29,731 |
| Net cash provided by financing activities | 14,082 |
| Effect of exchange rate changes on cash and cash equivalents | 1,097 |
| Increase (decrease) in cash and cash equivalents | -28,366 |
| Cash and cash equivalents and restricted cash, beginning of period | 183,615 |
| Cash and cash equivalents and restricted cash, end of period | 155,249 |
AbCellera Biologics Inc. (ABCL)
AbCellera Biologics Inc. (ABCL)